PHAXIAM Therapeutics (PHXM) 6-K ERYTECH Announces Results from TRYbeCA-1 Phase 3

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 6-K

________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2021

Commission File Number: 001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

________________________

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 Form 20-F S             Form 40-F £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   £

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release

On October 25, 2021, ERYTECH Pharma S.A. issued a press release announcing results from the TRYbeCA-1 phase 3 trial of eryaspase in patients with second-line advanced pancreatic cancer.

A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

EXHIBITS

Exhibit	Description
99.1	Press Release dated October 25, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		ERYTECH Pharma S.A.
Date:	October 25, 2021	By:	/s/ Eric Soyer
			Name Eric Soyer
			Title: Chief Financial Officer and Chief Operating Officer